Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ

VernacularTitle:玻璃体注射 Bevacizumab 治疗26例Ⅰ区早产儿视网膜病变
Author: Feng, CHEN ; Dao-Man, XIANG ; Jian-Xun, WANG ; Tian, LIU
Publication Type:Journal Article
Keywords: threshold retinopathy of prematurity; pre-threshold retinopathy of prematurity; acute posterior retinopathy of prematurity; intravitreal injection; bevacizumab
From: International Eye Science 2016;16(7):1363-1365
CountryChina
Language:Chinese
Abstract: AIM: To investigate the clinical effects of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity (ROP) in Zone Ⅰ.
METHODS:A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high - risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre - threshold ROP, threshold ROP and acute posterior ROP ( APROP ). Postoperative effects were compared.
RESULTS:There were 26 infants (52 eyes) diagnosed as ROP in Zone Ⅰ, including 3 infants( 6 eyes) with pre -threshold ROP, 15 infants (30 eyes) with threshold ROP and 8 infants (16 eyes) with APROP. The first operation recovery rate of three groups respectively were 100% (6 /6), 60% ( 18 / 30 ) and 75% ( 12 / 16 ), which were not significantly different (P>0. 05).
CONCLUSION:Intravitreal bevacizumab for ROP in ZoneⅠ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.